STOCK TITAN
  1. Home
  2. Sec-filings
  3. VERA
  4. [Form 4] Vera Therapeutics, Inc. Insider Trading Activity

Equity awards for Vera Therapeutics (VERA) Chief Regulatory Officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Boman Nancy Lee reported acquisition or exercise transactions in this Form 4 filing.

Vera Therapeutics, Inc. reported equity awards to Chief Regulatory Officer Nancy Lee Boman. On August 3, 2026 she received stock options over 63,011 Class A shares at $32.23 per share, expiring August 2, 2036, plus 44,987 RSUs under the 2024 Inducement Plan vesting from 2027 to 2030, each award subject to continuous service.

Positive

  • None.

Negative

  • None.
Insider Boman Nancy Lee
Role Chief Regulatory Officer
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) F2 63,011 $0.00 $0.00
Grant/Award Class A Common Stock F1 44,987 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 63,011 shares (Direct); Class A Common Stock — 44,987 shares (Direct)
Footnotes (2)
  1. F1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs, rounded to the nearest whole share, vest on each of August 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
  2. F2. 12/48ths of the shares subject to the stock option will vest and become exercisable on August 3, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
Stock options granted 63,011 shares Stock Option (right to buy) awarded on August 3, 2026
Option exercise price $32.23 per share Exercise price for 63,011-share stock option grant
Option expiration August 2, 2036 Expiration date of reported stock option grant
RSUs granted 44,987 shares Class A Common Stock underlying RSUs under 2024 Inducement Plan
RSU vesting dates August 20, 2027, 2028, 2029, 2030 Each date 1/4 of RSUs vest, subject to continuous service
Initial option vesting 12/48 of shares on August 3, 2027 Cliff vesting portion of 63,011-share stock option grant
restricted stock units ("RSUs") financial
"underlying the restricted stock units ("RSUs") granted under the Issuer's 2024"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2024 Inducement Plan financial
"RSUs granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs"
continuous service financial
"subject to the Reporting Person's continuous service through each vesting date."
vest and become exercisable financial
"shares subject to the stock option will vest and become exercisable on August 3, 2027"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider equity awards did Vera Therapeutics (VERA) grant in this Form 4?
Vera Therapeutics granted Chief Regulatory Officer Nancy Lee Boman 63,011 stock options and 44,987 RSUs. The options cover Class A Common Stock at $32.23 per share, and the RSUs represent future shares under the 2024 Inducement Plan, vesting over several years.

How many RSUs were granted to Nancy Lee Boman by Vera Therapeutics (VERA)?
Nancy Lee Boman was granted 44,987 RSUs linked to Class A Common Stock. These RSUs were issued under Vera Therapeutics' 2024 Inducement Plan and vest in four equal installments on August 20 of 2027, 2028, 2029 and 2030, assuming continuous service.

What are the vesting terms of the RSUs reported by Vera Therapeutics (VERA)?
The 44,987 RSUs vest in four equal parts: 1/4 of the RSUs on each of August 20, 2027, 2028, 2029 and 2030. Each vesting installment is conditioned on the reporting person’s continuous service through the applicable vesting date.

What are the key terms of the stock options in Vera Therapeutics (VERA)'s Form 4?
The stock option grant covers 63,011 shares of Class A Common Stock at an exercise price of $32.23 per share, expiring August 2, 2036. 12/48 of the shares vest on August 3, 2027, with 1/48 vesting monthly thereafter, subject to continuous service.

Were the Vera Therapeutics (VERA) equity grants reported under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked, indicating these equity awards were not reported as granted under a pre-arranged Rule 10b5-1 trading plan for the reporting person.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Boman Nancy Lee
(Last)(First)(Middle)
C/O VERA THERAPEUTICS, INC.
2000 SIERRA POINT PARKWAY, SUITE 1200
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Regulatory Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/03/2026A44,987(1)A$044,987D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$32.2308/03/2026A63,011 (2)08/02/2036Class A Common Stock63,011$063,011D
Explanation of Responses:
1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs, rounded to the nearest whole share, vest on each of August 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
2. 12/48ths of the shares subject to the stock option will vest and become exercisable on August 3, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
/s/ Joseph R. Young, Attorney-in-Fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR